Company ProfilePremium

International Flavors & Fragrances Inc. (IFF)

Company Profile Analysis

Ticker: IFF

ESOMAR 23 Corporate BadgeISO Certifications Badge
International Flavors & Fragrances Inc. (IFF) - Consumer Goods showcase

Year Founded & Workforce

1889

21,500 Employees

Industry

Consumer Goods
International Flavors & Fragrances Inc. (IFF) logo

International Flavors & Fragrances Inc. (IFF) Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

International Flavors & Fragrances Inc. (IFF) Overview

IFF is one of the world's "big four" flavour-and-fragrance houses and, following the 2021 merger with DuPont Nutrition & Biosciences, the broadest specialty-ingredients platform in consumer goods. The company is now in the final phase of a multi-year portfolio simplification: having divested 13 non-core businesses for roughly US$10bn of gross proceeds, it agreed in May 2026 to sell its largest and lowest-margin unit, Food Ingredients, to CVC Capital Partners for an enterprise value of ~US$4.3bn. The go-forward company comprises three innovation-led segments — Taste, Scent and Health & Biosciences — guided to ~US$7.4–7.6bn of 2026 sales at a ~21% adjusted operating EBITDA margin, with leading positions in flavours, fine and consumer fragrance, enzymes, cultures and probiotics. The investment debate centres on whether the slimmer, higher-margin IFF can re-rate towards Givaudan-like multiples once deleveraging, a US$2.5bn buyback and resolution of the global fragrance antitrust investigations are delivered.


What the company does

IFF designs, manufactures and sells proprietary ingredient systems that determine how consumer products taste, smell, feel and perform. Its products are almost never visible to the end consumer: they are formulated into customers' beverages, dairy products, snacks, savoury foods, sweets, dietary supplements, perfumes, detergents, shampoos, home-care products, animal feed, biofuels and industrial processes.

The company's own boilerplate (2026) describes IFF as a business that "makes joy through science, creativity and heart" and positions itself as the global leader in flavours, fragrances, and health and biosciences — a description that, notably, dropped the words "food ingredients" between the February 2026 and August 2026 releases, mirroring the decision to divest that segment.

Business model

Co-creation and formulation model (Taste, Scent): IFF wins "briefs" from consumer-goods customers and creates bespoke, confidential formulas (flavour compounds, fragrance compounds). Once a formula is adopted into a customer's product it typically remains for the product's lifecycle, producing recurring, annuity-like revenue. Switching costs are high because reformulation risks consumer rejection. Many large customers operate "core lists" of a small number of approved suppliers, which is a structural barrier to entry.

Science-platform model (Health & Biosciences): Revenue derives from proprietary enzymes, cultures, probiotics and biotech-derived ingredients produced through fermentation. Value is underpinned by strain libraries, protein-engineering IP and large-scale fermentation capacity (the DuPont/Genencor/Danisco heritage).

  • Ingredient-supply model (Fragrance Ingredients and, until divested, Food Ingredients). More volume-driven, partly commodity-exposed businesses (aroma chemicals; texturants, emulsifiers, plant proteins).

Revenue model mix

Revenue typeEstimated shareBasis
Product sales (compounds, ingredients, enzymes, cultures)~100%10-K revenue recognition; services embedded
Services billed separatelyNot material / not publicly disclosed—
Licensing / royaltiesNot material / not publicly disclosed—

IFF is overwhelmingly a product company: revenue is recognised on shipment of physical ingredients. Formulation, sensory and application services are bundled into product pricing rather than billed separately. There is no material subscription or licensing revenue disclosed. A small portion of H&B revenue derives from technology collaborations, but this is not separately quantified (not publicly disclosed).

Value-chain position

IFF sits in the middle of the chain: upstream it buys natural raw materials (citrus oils, vanilla, botanicals, crude sulphate turpentine, petrochemical intermediates, agricultural commodities, sugars for fermentation) and downstream it sells to brand owners and contract manufacturers. Value capture comes from formulation know-how, regulatory dossiers, application labs and fermentation IP rather than from raw-material processing.

Customer types and end-markets

Customer typeExamples of end usePrimary IFF segment
Global food & beverage multinationalsSoft drinks, dairy, savoury, sweet goodsTaste; (Food Ingredients — divesting)
Regional/local food & beverage manufacturersLocal beverages, bakery, snacksTaste
Fine-fragrance houses and luxury/prestige brandsPerfumes, eau de toiletteScent (Fine Fragrance)
Home & personal-care multinationalsDetergents, fabric care, shampoo, soapScent (Consumer Fragrance); H&B (Home & Personal Care enzymes)
Dietary-supplement and infant-nutrition companiesProbiotics, HMOsH&B (Health)
Animal-nutrition and feed producersFeed enzymes (phytase), probioticsH&B (Animal Nutrition)
Grain processors and biofuel producersEthanol, starch, sweetener processingH&B (Grain Processing)
Pharmaceutical manufacturersExcipients (until 2025 disposal)Pharma Solutions (divested May 2025)

Independent characterisation

IFF is best understood today as a company in transition from a sprawling, leverage-burdened conglomerate (post-Frutarom and DuPont N&B) to a focused "taste-scent-biosciences" pure play. On a continuing-operations basis it generated a 21.8% adjusted operating EBITDA margin in H1 2026, versus 19.2% for the full 2025 portfolio — the arithmetic of the portfolio change is margin-accretive, but the company will be roughly one-third smaller by revenue than it was in 2024. Its closest strategic analogue is Givaudan, which has historically commanded a significant valuation premium; the core thesis of the turnaround is closing that gap.

Strategy

Stated strategy (themes from 2025–2026 filings and releases)

  1. Portfolio focus on three innovation-led pillars — Taste, Scent and Health & Biosciences. Management describes the Food Ingredients sale as the step that creates a "simpler, higher-growth, higher-margin company with enhanced cash generation."

  2. Business-led operating model. Implemented in 2025 to strengthen accountability, customer focus and decision speed, with emphasis on margin improvement, cash generation and execution consistency (Chair's letter, 2026 Proxy).

  3. Reinvestment in R&D, commercial capabilities and capacity (FY2025 R&D US$694m; capex 5.5% of sales).

  4. Productivity and cost discipline via the IFF Productivity Program and expanded GBS centres with AI automation.

  5. Balance-sheet strength and disciplined capital allocation — leverage target 2.0–2.5x; investment in the business; return of excess capital.

  6. Responsible AI adoption — new AI Policy and AI Governance Framework (March 2026), agentic AI embedded in IT, GBS, R&D and Finance.

  7. Sustainability ("Do More Good") — four pillars: conscious sourcing, partnerships of impact, intentional innovation, operating for the future.

Strategic initiatives register (last 24 months)

DateInitiativeTypeTarget / detail
2024–2026IFF Productivity ProgramCost / restructuringSeverance, site closures; FY2025 charge US$70m; H1 2026 US$10m
Feb 2025Business-led operating model and new ELTOrganisationSegment presidents own P&Ls
2,025Debt tender offers using Pharma proceedsDeleveragingUS$2.9bn principal repaid in FY2025; US$488m gain
Q4 2025US$500m share-repurchase authorisationCapital returnFirst buyback since merger
Q4 2025Food Ingredients strategic review / sale processPortfolioConcluded with CVC deal
Mar 2026AI Policy and AI Governance FrameworkTechnology / governanceAligned with EU AI Act prohibitions
2,026Expanded GBS reorganisation incl. AICostCustomer service, supply chain, logistics
May 2026Food Ingredients sale to CVCPortfolioEV ~US$4.3bn (~10x EBITDA)
Jul 2026SuanNutra carve-outPortfolio~US$170m revenue exited
Aug 2026Sequenced use-of-proceeds frameworkCapital allocation>US$1bn debt reduction; US$2.5bn buyback by end-2027
Aug 2026Stranded-cost remediationCost~US$100m stranded costs; ~two-thirds eliminated within 12 months of close, substantially all within 24 months
2,026AQUASCENT™, Omni-Bos™ PHY launches; Brazil enzyme centreInnovation / footprintSee Section 13

Management targets and guidance

MetricFY2026 guidance (original, 11 Feb 2026; total company)FY2026 guidance (4 Aug 2026; continuing operations)
Net salesUS$10.5–10.8bnUS$7.4–7.6bn (excl. ~US$3.2bn discontinued)
Adjusted operating EBITDAUS$2.05–2.15bnUS$1.53–1.60bn (excl. ~US$520m discontinued)
Comparable currency-neutral sales growth1–4%2–4%
Comparable currency-neutral adj. EBITDA growth3–8%4–8%
FX impact~+1% sales; ~0% EBITDA~+1% sales; ~+2% EBITDA
Divestiture impact~−5% to both sales and EBITDAEmbedded in continuing basis
Leverage target—2.0–2.5x net debt/EBITDA

Products & Services

IFF does not publish a priced catalogue; pricing is bespoke and contract-based (not publicly disclosed). The catalogue below is organised by segment and lists named platforms and recently launched offerings identified in company releases. Launch years are given where disclosed; otherwise "NA".

Taste

OfferingDescription / capabilitiesTarget customerLaunch / latestNotes
Flavour compounds (beverage)Custom flavour systems for carbonated soft drinks, juices, RTD tea/coffee, alcoholic beveragesBeverage multinationals and regional bottlersOngoingCore of Taste
Flavour compounds (sweet & dairy)Vanilla, fruit, dairy and confectionery profiles; dairy-specific taste solutionsDairy, bakery, confectioneryOngoingIFF published "Dear Dairy: The Life Stages Guide" consumer-insight resource (2026)
Flavour compounds (savoury)Savoury, snack seasoning and meat-alternative flavoursSnack, prepared-food and plant-based brandsOngoingSavoury Solutions business itself sold to PAI (2023)
Taste modulation / sugar & salt reductionSweetness enhancers, masking agents, mouthfeel modifiersReformulating F&B brandsOngoingBenefits from GLP-1 and health-driven reformulation
Natural flavoursNatural-origin extracts and flavour preparationsClean-label brandsOngoingSome Peru-based localised flavour activities sold to SuanNutra (2026)
Designed/consumer-insight servicesSensory science, consumer insight, application labsAll Taste customersOngoingBundled, not separately billed

Scent

OfferingDescription / capabilitiesTarget customerLaunch / latestNotes
Fine FragrancePerfumer-created fragrances for prestige, mass-prestige and niche brandsLuxury houses, celebrity and niche brandsOngoingDouble-digit growth in FY2025; low-single-digit in Q2 2026 owing to the Middle East conflict
AQUASCENT™Vegan, water-based (alcohol-free) carrier for fine fragrance using biodegradable materials; improved olfactive performance and clarity; shipping benefitsFine-fragrance brands2,026New scent-technology platform
Consumer FragranceFragrances for fabric care, home care, personal wash, hair care, toiletriesHome & personal-care multinationalsOngoingHigh-single-digit growth in Q2 2026
Fragrance IngredientsAroma chemicals and specialty molecules (captive and merchant sales)Fragrance houses, compoundersOngoingDouble-digit growth in Q2 2026 after FY2025 commodity declines
LMR Naturals by IFFNatural raw materials for perfumery, cosmetics and flavours (Grasse, France)Perfumers, cosmetic brandsOngoingShowcased at SIMPPAR 2026
Encapsulation / delivery systemsFragrance-release technologies for longevity in detergents and personal careConsumer-goods majorsOngoing—
CitraSourceCitrus-based ingredientsFlavour and fragrance usersHeld for sale (2026)US$27m loss on assets held for sale booked Q2 2026

Health & Biosciences

OfferingDescription / capabilitiesTarget customerLaunch / latestNotes
Probiotics (incl. HOWARU® heritage line)Clinically studied probiotic strains for supplements and foodsSupplement and infant-nutrition brandsOngoingBrand naming per DuPont heritage (confirm current branding)
Human milk oligosaccharides (HMOs)Infant-nutrition prebioticsInfant-formula makersOngoingHealth business; North America softness in Q4 2025
Food cultures & food enzymesDairy cultures, bakery and brewing enzymes, bioprotectionDairy, bakery, beverage processorsOngoingFood Biosciences grew high-single-digit in FY2025
Home & Personal Care enzymesProteases, amylases, lipases for detergents; biopolymersDetergent manufacturersOngoingMid-to-high single-digit growth FY2025
Omni-Bos™ PHYNovel phytase enzyme for dairy cattle improving nutrient utilisation and feed efficiencyDairy producers/feed integrators2026 (MEA and APAC first)Animal Nutrition innovation
Feed enzymes & probiotics (Animal Nutrition)Phytases, xylanases, direct-fed microbialsFeed producersOngoingDouble-digit growth in Q4 2025
Grain Processing enzymesEnzymes for fuel ethanol, starch, sweetener processingEthanol producers, wet millersOngoingLed H&B growth in Q2 2026
Brazil enzyme centre & application labLatin American enzyme hub and application laboratoryLatAm customers2,026Expands regional footprint

Food Ingredients (discontinued; pending sale to CVC)

OfferingDescriptionStatus
TexturantsHydrocolloids (pectin, carrageenan, alginates, cellulosics for food)Transferring to CVC
Emulsifiers & SweetenersEmulsifiers and sweetening systemsTransferring to CVC
Protein Solutions / plant-basedPlant proteins and systemsTransferring to CVC
Systems & InclusionsIntegrated ingredient systems; inclusions (fruit preparations, pieces)Transferring to CVC; Inclusions grew double-digit in FY2025
Soy Crush, Concentrates & LecithinSoy processing and lecithinSold to Bunge, 2 Mar 2026

Natural specialties being sold to SuanNutra (agreement July 2026)

OfferingDescriptionStatus
Botanical extractsClinically supported branded botanical ingredients (e.g., olive-leaf extract)Sale expected to close by end-2026
Vitamins & mineralsFermented vitamins and mineralsAs above
Food enhancement / natural colours / antioxidantsNatural colours, antioxidants, natural betaineAs above
Localised flavour activities (Peru)Select flavour operationsAs above

Combined revenue ~US$170m (2025), ~600 employees, five manufacturing facilities in Europe, the US and Latin America; terms not disclosed.

Divested: Pharma Solutions (for completeness)

Excipients and functional ingredients for pharmaceuticals and nutraceuticals (sold to Roquette, closed 1 May 2025); nitrocellulose (sold 9 May 2025).

Financial Narrative

H1 2026 figures are on the new continuing-operations basis and are not comparable with full-year columns.

Income statement

Note: the 2026 proxy reports FY2025 diluted EPS of US$(1.41) whereas the results release reports US$(1.46); the discrepancy likely reflects a post-release adjustment in the 10-K (both cited; the 10-K figure should prevail). FY2023 DPS reflects four quarterly payments of US$0.81; the reset to US$0.40 per quarter took effect from Q1 2024.

Revenue CAGR FY2021–FY2025 (reported): (10,890 / 11,656)^(1/4) − 1 ≈ −1.7% p.a., entirely driven by divestitures; comparable currency-neutral growth was positive in FY2024 (~6%, as referenced by management) and FY2025 (+2%).

Commentary. Reported revenue has been flat-to-down since the 2022 peak (US$12.44bn) because IFF has been selling businesses faster than it has grown. Underlying performance improved under Fyrwald: comparable currency-neutral adjusted EBITDA grew 7% in FY2025 on just 2% organic sales growth, reflecting productivity programmes. GAAP earnings remain noisy. FY2025's operating loss was caused by a US$1,153m goodwill impairment in the Food Ingredients reporting unit (the market-implied value revealed by the sale process), partially offset below the operating line by a US$488m gain on debt extinguishment (bonds repurchased below par via tender offers). Recurring below-the-line charges include regulatory costs of US$106m in FY2025 (legal fees and provisions for the fragrance investigations) and divestiture costs of US$125m.

Balance sheet

H1 2026 (30 June 2026, continuing/discontinued presentation): cash US$569m; total assets US$25,154m; goodwill & intangibles (continuing) US$11,877m; current assets of discontinued operations US$4,840m; short-term borrowings US$964m; long-term debt US$4,735m; total debt US$5,735m; net debt US$5,166m; equity US$14,009m.

Commentary. The balance sheet has been transformed by disposals. Long-term debt fell by ~US$2.8bn in FY2025 as Pharma Solutions proceeds (~US$2.7bn net received in H1 2025) funded tender offers. Net debt to credit-adjusted EBITDA fell from ~3.8x at end-2024 to 2.6x at end-2025 and 2.5x at 30 June 2026, against a covenant maximum of 3.75x. Goodwill and intangibles still represent ~56% of total assets, a legacy of the Frutarom and DuPont N&B transactions, which keeps impairment risk elevated. Management targets 2.0–2.5x net debt/EBITDA and plans >US$1bn of further debt reduction from CVC proceeds.

Cash flow

H1 2026 (incl. discontinued operations): CFO US$679m (+US$311m y/y); capex US$301m; FCF US$378m (+US$284m y/y); dividends US$204m; treasury purchases US$71m; net commercial-paper repayment US$264m; disposal proceeds US$201m.

Commentary. FY2025 free cash flow (US$256m) was weak because capex rose to ~5.5% of sales (capacity expansion and reinvestment) while operating cash flow fell on lower incentive-accrual timing and working capital. H1 2026 shows a sharp recovery, driven by payables (+US$288m) and lower incentive payouts. Management has flagged up to ~US$100m of H2 2026 working-capital headwind from the Food Ingredients separation (unwinding of factoring arrangements and inventory builds).

Ratios

Ratios computed by the analyst from reported figures; FY2024 net debt/EBITDA of ~3.8x is as stated in the 2026 proxy. Days payables were not disclosed separately in the condensed balance sheet, so a full cash conversion cycle is NA. ROIC is not disclosed by the company and is not estimated. The deterioration in DIO to ~118 days is notable and consistent with management's focus on working-capital release.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Reportable Segments by Period

PeriodReportable segmentsNotes

FY2021–FY2023

Nourish; Scent; Health & Biosciences; Pharma Solutions

Post-DuPont N&B structure

FY2024–FY2025

Taste; Food Ingredients; Health & Biosciences; Scent; Pharma Solutions

Nourish split into Taste and Food Ingredients (business-unit reorganisation, 2024). Pharma Solutions sold 1 May 2025

From Q2 2026 (continuing operations)

Taste; Health & Biosciences; Scent

Food Ingredients disposal group and SCL disposal group reported as discontinued operations, with comparatives recast

Segment Overview

SegmentBusiness units / contentsStatus

Taste

Flavour compounds for beverages, sweet, savoury, dairy; taste-modulation and sugar/salt-reduction systems; natural flavours

Continuing

Scent

Fine Fragrance; Consumer Fragrance (fabric care, home care, personal wash, hair care); Fragrance Ingredients (aroma chemicals, naturals incl. LMR Naturals); CitraSource (citrus; classified held for sale in 2026)

Continuing (CitraSource being exited)

Health & Biosciences

Health (probiotics, HMOs, dietary-supplement actives); Food Biosciences (cultures, food enzymes); Home & Personal Care (detergent enzymes, biopolymers); Animal Nutrition (feed enzymes, probiotics); Grain Processing (enzymes for ethanol, starch and sweeteners)

Continuing

Food Ingredients

Texturants, emulsifiers & sweeteners, plant-based proteins (Protein Solutions), systems, inclusions, SCL (sold)

Discontinued; sale to CVC pending

Pharma Solutions

Excipients (cellulosics, alginates), nitrocellulose

Divested May 2025

Segment net sales (USD Mn)

Segment net sales (USD Mn)FY2024FY2025

Taste

2,4282,481

Food Ingredients

3,3653,278

Health & Biosciences

2,2032,283

Scent

2,4392,479

Pharma Solutions

1,049369

Total net sales

11,48410,890

Segment adjusted operating EBITDA (USD Mn)

Segment adjusted operating EBITDA (USD Mn)FY2024FY2025

Taste

460478

Food Ingredients

408423

Health & Biosciences

577594

Scent

545515

Pharma Solutions

21576

Total adjusted operating EBITDA

2,2052,086

Segment adjusted operating EBITDA margin (%)

Segment adjusted operating EBITDA margin (%)FY2024FY2025

Taste

18.919.3

Food Ingredients

12.112.9

Health & Biosciences

26.226.0

Scent

22.320.8

Pharma Solutions

20.520.6

Consolidated

19.219.2

Segment Revenue

SegmentReported sales growth FY2025 (%)Comparable currency-neutral sales growth (%)Comparable currency-neutral adj. EBITDA growth (%)% of FY2025 sales

Taste

241022.8

Food Ingredients

-3-31030.1

Health & Biosciences

43721.0

Scent

23222.8

Pharma Solutions

-6512163.4

Consolidated

-527100.0

Continuing ops net sales (USD Mn)

Continuing ops net sales (USD Mn)H1 2025H1 2026

Taste

1,3041,368

Health & Biosciences

1,0791,176

Scent

1,2171,316

Pharma Solutions

3690

Total continuing ops

3,9693,860

Continuing ops adjusted operating EBITDA (USD Mn)

Continuing ops adjusted operating EBITDA (USD Mn)H1 2025H1 2026

Taste

246276

Health & Biosciences

262290

Scent

259275

Pharma Solutions

760

Total

843841

Continuing ops adj. EBITDA margin (%)

Continuing ops adj. EBITDA margin (%)H1 2025H1 2026

Taste

18.920.2

Health & Biosciences

24.324.7

Scent

21.320.9

Consolidated

21.221.8

Q2 2026 Segment Details

Q2 2026 segmentReported sales (USD Mn)Reported growth (%)Comparable currency-neutral sales growth (%)Adj. EBITDA (USD Mn)Margin (%)

Taste

6885412418.0

Health & Biosciences

6018515025.0

Scent

66510813420.2

Consolidated (continuing)

1,9542640820.9

Income statement (USD Mn)

Income statement (USD Mn)FY2021FY2022FY2023FY2024FY2025

Net sales

11,65612,44011,47911,48410,890

Cost of sales

———7,3606,952

Gross profit

———4,1243,938

Research & development expense

———671694

Selling & administrative expense

———1,9951,834

Amortisation of acquisition intangibles

———610568

Goodwill impairment

———641,153

Operating profit (loss)

———766-382

Interest expense

———305229

Income (loss) before taxes

———308-412

Net income (loss) attributable to IFF

268-1,871-2,567263-374

Adjusted operating EBITDA (non-GAAP)

———2,2052,086

EBITDA (GAAP operating profit + D&A)

———1,781580

Per share (USD)

Per share (USD)FY2021FY2022FY2023FY2024FY2025

Diluted EPS (GAAP)

1.12-7.32-10.051.04-1.46

Basic EPS (GAAP)

———1.04-1.46

Adjusted diluted EPS (non-GAAP)

———2.442.52

Adjusted EPS ex amortisation (non-GAAP)

———4.224.20

Dividends declared per share

——3.241.601.60

Margins (%)

Margins (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

———35.936.2

Operating margin (GAAP)

———6.7-3.5

Adjusted operating EBITDA margin

———19.219.2

Net margin (GAAP)

2.3-15.0-22.42.3-3.4

Balance Sheet

Balance sheet (USD Mn, year-end)FY2023FY2024FY2025

Cash & cash equivalents

703469590

Receivables, net

—1,6241,731

Inventories

—2,1332,245

Assets held for sale

—3,056151

Total current assets

—7,9685,594

Property, plant & equipment, net

—3,7394,029

Goodwill & other intangibles, net

—15,52014,312

Total assets

—28,72325,537

Short-term borrowings

—1,4131,254

Long-term debt

—7,5644,740

Total debt (incl. finance leases, company definition)

——6,026

Net debt (company definition)

——5,436

Total current liabilities

—4,3523,933

Shareholders' equity

—13,86914,180

Working capital (current assets − current liabilities)

—3,6161,661

Cash flow (USD Mn)

Cash flow (USD Mn)FY2024FY2025

Net cash from operating activities

1,070850

Capital expenditures (PP&E)

463594

Free cash flow (CFO − capex)

607256

Dividends paid

514409

Share repurchases (treasury stock)

038

Net proceeds from business disposals

8752,743

Principal payments of debt

1,0302,913

Depreciation & amortisation

1,015962

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE (net income / year-end equity, %)

1.9-2.6

ROA (net income / year-end total assets, %)

0.9-1.5

Current ratio (x)

1.831.42

Debt / equity (x, borrowings only)

0.650.42

Net debt / credit-adjusted EBITDA (x, company)

3.82.6

Adjusted operating EBITDA / interest expense (x)

7.29.1

GAAP operating profit / interest expense (x)

2.5-1.7

Asset turnover (sales / year-end assets, x)

0.400.43

Days sales outstanding (receivables / sales × 365)

5258

Days inventory outstanding (inventory / COGS × 365)

106118

Geographic net sales (USD Mn)

Geographic net sales (USD Mn)FY2023FY2024FY2025

Total

11,47911,48410,890

Region Overview

RegionSignalSource

North America

Taste Q4 2025 growth led by a strong North American performance; H&B Health business soft in North America in Q4 2025

FY2025 release

All regions (Taste)

Broad-based growth in all regions in FY2025, Q1 2026 and Q2 2026

FY2025 and Q2 2026 releases

Middle East

Fine Fragrance growth slowed to low-single-digits in Q2 2026 owing to the Middle East conflict

Q2 2026 release

Russia

Food Ingredients lost sales due to Russia sanctions

Q4 2025 earnings call

Latin America

New enzyme centre and application lab in Brazil (2026) signals investment priority

Company announcement

Middle East, Africa, APAC

First-launch markets for Omni-Bos™ PHY dairy-cattle phytase

Company announcement

Market Data Point Details

Market data pointValueDate / source

Share price

US$77.53

Close 10 Jul 2026 (stockanalysis.com)

Share price

US$74.43

~21 May 2026 (Investing.com)

Share price

US$72.85

Spring 2026 (Yahoo Finance FR)

52-week range

US$59.14–84.45

Yahoo Finance (spring 2026)

Market capitalisation

~US$19.8bn

10 Jul 2026

Shares outstanding

~255.3m

Mid-2026

1-year TSR

+1.8%

Boardroom Alpha (May 2026)

3-year TSR

+1.3% (cumulative/annualised basis not specified)

Boardroom Alpha (May 2026)

Valuation Snapshot

MultipleValueBasis

P/E (adjusted EPS ex amortisation FY2025 US$4.20)

~18.5x

FY2025

EV/EBITDA (total company incl. discontinued)

~12.0x

EV ≈ US$19.8bn + US$5.17bn net debt ≈ US$25.0bn; ÷ ~US$2.09bn 2026E total adj. EBITDA (midpoint continuing US$1.565bn + ~US$0.52bn discontinued)

EV/Sales (total company)

~2.3x

÷ ~US$10.7bn 2026E total sales

P/B

~1.4x

÷ US$14.0bn equity (30 Jun 2026)

Valuation history (x)

FY2021

FY2022

Analyst Ratings & Targets

BrokerRatingPrice target (USD)Note

Benchmark (initiation)

Buy

100

Sees FI sale unlocking value

BofA

Buy

98 (raised from 92); earlier cut to 92 from 99 after FI deal

Sequence of revisions in 2026

Morgan Stanley

Overweight

95 (from 93)

Higher peer multiples

JPMorgan

Overweight

92 (from 90)

—

Barclays (L. Lieberman)

Overweight

90 (from 80)

—

Oppenheimer

Outperform

90 (from 88)

—

Citi

Buy

88 (cut from 96)

—

Argus

Buy

85 (from 80)

—

Zacks

Rank #5 (Strong Sell)

—

Post-Q2 estimate cuts

Aggregate

~24 Buy / 8 Hold / 1 Sell

Mean target ~US$91 (Yahoo/Simply Wall St, 2026)

—

Dividends declared per share (USD)

Dividends declared per share (USD)FY2023FY2024FY2025

Dividend per share

3.241.601.60

Dividends paid (USD Mn)

Dividends paid (USD Mn)FY2024FY2025

Cash dividends paid

514409

Authorisation Details

AuthorisationDateSizeStatus

Initial authorisation

Q4 2025

US$500m

US$38m executed FY2025; US$71m in H1 2026; ~US$400m remaining rolled into new programme

Enhanced authorisation

4 Aug 2026

US$2.5bn total (incl. ~US$400m remaining)

US$500m ASR in H2 2026; US$2.0bn after FI close; completion targeted by end-2027

Credit Ratings

AgencyRatingOutlook

S&P Global Ratings

BBB (long-term) / A-2 (short-term)

Stable

Debt component (USD Mn)

Debt component (USD Mn)Value

Short-term borrowings (incl. commercial paper and current maturities)

964

Long-term debt

4,735

Total debt (incl. finance leases)

5,735

Cash & equivalents

569

Net debt

5,166

Credit-adjusted EBITDA (TTM, incl. discontinued)

2,056

Net debt / credit-adjusted EBITDA

2.5x (covenant maximum 3.75x)

Analyst Conclusions

Management guidance (continuing operations, FY2026)

MetricGuidance
Net salesUS$7.4–7.6bn
Adjusted operating EBITDAUS$1.53–1.60bn
Comparable currency-neutral sales growth2–4%
Comparable currency-neutral adj. EBITDA growth4–8%
FX~+1% sales; ~+2% EBITDA
H2 2026 implied sales growth~0–4%
Discontinued operations~US$3.2bn sales; ~US$520m adj. EBITDA

Consensus growth expectations

Q2 2026 commentary (Zacks Rank #5) indicates downward estimate revisions after the recast, though part of the apparent "miss" (US$0.82 vs. US$1.14) reflects consensus that had not yet been rebased for discontinued operations.

Bull case

  1. Pure-play re-rating. The continuing business delivered a 21.8% adjusted EBITDA margin in H1 2026 with volume-led 4% organic growth; with Food Ingredients sold at ~10x EBITDA, the residual company trades at a discount to peers despite a similar mix.

  2. Accretive capital return. A US$2.5bn buyback equates to roughly an eighth of the market cap; funded mainly by ~US$3.8bn of net CVC proceeds while still reducing debt by >US$1bn.

  3. Antitrust de-risking. The DOJ closed its investigation in February 2026 and IFF has already settled a substantial portion of US civil claims for only US$26m.

Bear case

  1. Shrinking earnings base and stranded costs. Continuing EBITDA of ~US$1.57bn (midpoint) is far below the FY2024 total (US$2.2bn); ~US$100m of stranded costs and dis-synergies must be eliminated, and EPS dilution will precede buyback accretion.

  2. Regulatory fines. EC, CMA, COMCO, Mexico, India (two cases) and Singapore remain open; EC cartel fines can reach up to 10% of global turnover, and IFF is already booking provisions (Q2 2026 regulatory costs US$71m).

  3. Margin squeeze in H2 2026 and Scent fragility. Input inflation with pricing lagging into 2027, Middle East exposure in Fine Fragrance, and a 150bp Scent margin decline in FY2025 could cap upside.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Q3 2026 results and FY2026 guidance reaffirmation~4–5 Nov 2026
Execution of US$500m ASRH2 2026
SuanNutra and CitraSource closingsBy end-2026
FY2026 results and first full-year continuing-ops outlook~Feb 2027
EC / CMA / COMCO antitrust decisions or settlementsUncertain
CVC regulatory approvals and closingBy end-Q2 2027
Post-close US$2.0bn buyback and >US$1bn debt paydownH2 2027
Possible investor day with medium-term targets for the new IFFUnconfirmed
Icahn cooperation agreement expiry / renewalAround 2027 AGM notice deadline
Further rating actions (S&P, Moody's)Following FI close

Analyst verdict

IFF is approaching the end of a five-year unwind of the complexity and debt it assumed through the Frutarom acquisition and the DuPont Nutrition & Biosciences merger. The evidence that the turnaround is real is now reasonably strong: under Erik Fyrwald the company met its 2025 commitments, delivered 7% comparable currency-neutral EBITDA growth on modest top-line growth, cut net leverage from 3.8x to 2.5x, earned an S&P upgrade to BBB, and — most importantly — monetised its weakest segment at a respectable ~10x EBITDA. What remains is a three-segment company with ~US$7.5bn of sales, a margin profile in the low 20s and genuine scientific differentiation in enzymes, cultures and probiotics that none of its F&F peers fully replicates.

The equity, however, still prices in meaningful doubt. At roughly 12x total-company EBITDA and ~18–19x adjusted earnings excluding amortisation, IFF trades at a clear discount to the best-in-class flavour-and-fragrance houses. That discount is defensible for now: GAAP earnings are depressed by recurring "non-recurring" costs, goodwill still dwarfs tangible capital, the fragrance cartel investigations in Europe, the UK, Switzerland, Mexico, India and Singapore could yield material fines, and the CVC transaction will not close until mid-2027, leaving the US$2.0bn post-close buyback contingent.

On balance, the risk-reward skews modestly positive for investors with a 12–24-month horizon. The thesis hinges on three verifiable milestones: sustained 3–5% organic growth in the continuing segments through the H2 2026 cost squeeze; on-time closing of the CVC deal with stranded costs removed on the promised schedule; and an antitrust outcome in the EC process that is financially containable. Delivery on all three would justify a narrowing of the valuation gap to peers; a large EC fine or a slip in Scent margins would leave IFF as a cheaper but structurally lower-quality alternative to Givaudan. Monitor Q3 2026 results and ASR execution as the next proof points.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure in rolePrior rolesEducationAge

J. Erik Fyrwald

Chief Executive Officer; Director

Since 6 Feb 2024

CEO Syngenta Group (2016–2024); CEO Univar Solutions (2012–2016); Chairman & CEO Nalco (2008–2011); President Ecolab; 27 years at DuPont incl. VP & GM Nutrition & Health; director of Eli Lilly since 2005

BS Chemical Engineering, University of Delaware; Harvard AMP

66

Michael DeVeau

EVP & Chief Financial Officer

Since 1 Jan 2025

IFF since 2009: SVP Corporate Finance & IR; Divisional CFO Scent; Chief Strategy Officer; previously PepsiCo (IR, finance, corp. dev.) and Citigroup equity research

BA Fordham; INSEAD Global Executive Leadership Program

—

Leticia Gonçalves Lourenço

President, Health & Biosciences

Since 1 Mar 2025

ADM President, Precision Fermentation & ADM Ventures; senior roles at Bayer and Monsanto; director of Emerson Electric

——

Andres (Andy) Muller

President, Food Ingredients

Since 2025

———

Ana Paula Teles de Mendonça

President, Scent

————

Yuvraj Arora

Named executive officer (role per 2026 proxy; believed President, Taste — confirm)

————

Deborah Borg

Section 16 officer (believed EVP, Chief People & Culture Officer — confirm)

————

Brynn Samson

SVP, Chief Compliance Officer & Corporate Secretary

————

Michael Bender

Head of Investor Relations

————

Directors' Remuneration

ItemValueSource

CEO FY2025 annualised total compensation

US$15,002,866

2026 Proxy, pay-ratio section

CEO FY2024 annualised total compensation (incl. one-time sign-on awards)

US$24,248,498

2025 Proxy

Median employee FY2025 total compensation

US$62,828

2026 Proxy

CEO pay ratio FY2025

239:1

2026 Proxy

CEO pay ratio FY2024

381:1 (231:1 excluding sign-on and relocation)

2025 Proxy

CEO sign-on awards (granted 1 Mar 2024)

RSUs US$4,268,250 (3-yr cliff) + PSUs US$4,914,250 (TSR/price-hurdle based)

2025 Proxy

CEO deferral

Deferred US$2,908,800 FY2024 annual incentive into the non-qualified plan

2026 Proxy

Board of Directors

DirectorPrimary occupationJoinedAge (3 Mar 2026)IndependentCommittees (post-AGM 2026)

Kevin O'Byrne

Former CFO & Director, J Sainsbury plc; Chair of Centrica plc

202361

Yes

Non-executive Chair; Governance & Corporate Responsibility

J. Erik Fyrwald

CEO, IFF

202466

No

—

Virginia C. Drosos

Former CEO, Signet Jewelers; ex-P&G Group President Global Beauty

202563

Yes

Chair, Human Capital & Compensation; Innovation

Paul J. Fribourg

Chairman & CEO, Continental Grain; director Loews, Estée Lauder, Syngenta Group

202572

Yes

Audit

Brett Icahn

Investor and portfolio manager, Icahn Capital (Icahn designee)

202546

Yes

Audit

Cynthia T. Jamison

Former CFO AquaSpy; Chair of Darden Restaurants; CPA

202566

Yes

Chair, Audit; Governance & Corporate Responsibility

Mehmood Khan

CEO, Hevolution Foundation; ex-PepsiCo Vice Chairman & CSO

202567

Yes

Chair, Innovation; Governance & Corporate Responsibility

Jesus B. Mantas

Retired senior executive, IBM Consulting; director Biogen

202557

Yes

Audit; Human Capital & Compensation; Innovation

Richard Mulligan

Mallinckrodt Professor of Genetics, Emeritus, Harvard Medical School (mutually agreed Icahn-cooperation director)

202571

Yes

Innovation

Dawn C. Willoughby

Former EVP & COO, The Clorox Company; director J.M. Smucker, TE Connectivity

202356

Yes

Chair, Governance & Corporate Responsibility; Human Capital & Compensation

Board & Management Changes

DateChangeContext

Feb 2024

Fyrwald succeeds Clyburn as CEO

Board sought turnaround leadership

10 Dec 2024 (announced)

DeVeau named CFO effective 1 Jan 2025; Glenn Richter retires

Internal succession

20 Feb 2025

ELT aligned with new operating model; Simon Herriott (H&B) steps down after 21 years; Gonçalves Lourenço hired

Business-led operating model

May 2025

O'Byrne becomes Chair; Ferguson, Davidson, Gold leave

Board refresh

Oct 2025

Intrieri and Paláu-Hernández replaced by Brett Icahn and Mulligan

Icahn agreement mechanics

Apr 2026

Ferraro, Costa, Boor leave; board reduced to 10

Further refresh

Major Shareholders

Holder categoryDetail

Top 10 institutional holders

5%+ holders are listed on p.28 of the 2026 Proxy

Insider ownership

Individually below 1%; CEO direct holding ≈0.03–0.035% (third-party data). Directors and executive officers as a group: NA

Notable new holder

Heartland Mid Cap Value Fund described IFF as a new "deep value" holding (2026)

Competitive Landscape

Key Competitors

CompetitorHQSegments where it competes with IFFApprox. latest annual revenueNotes

Givaudan

Switzerland

Taste, Scent

—

Industry leader; premium valuation

DSM-Firmenich

Switzerland/Netherlands

Taste, Scent, H&B (nutrition, enzymes)

~€12.8bn (FY2024 group)

Formed 2023; restructuring Animal Nutrition & Health

Symrise

Germany

Taste, Scent, pet food

~€5.0bn (FY2024)

Strong in aroma molecules and pet food

Kerry Group

Ireland

Taste (taste & nutrition systems), Food Ingredients

~€7bn (FY2024)

Integrated taste/nutrition systems

Novonesis (Novozymes + Chr. Hansen)

Denmark

H&B (enzymes, cultures, probiotics)

~€4bn (FY2024)

Primary biosolutions rival

Takasago

Japan

Taste, Scent, aroma chemicals

—

Strong in Asia; menthol

Mane

France (private)

Taste, Scent

NA (private)

Family-owned; agile mid-market

Robertet

France

Scent, naturals, Taste

—

Naturals specialist

Sensient Technologies

USA

Taste, colours

—

Colours leadership

ADM (Nutrition)

USA

Taste, Food Ingredients, Health

—

Flavours (Wild) and proteins

Tate & Lyle

UK

Food Ingredients (texturants, sweeteners)

—

Competes with divested FI business

AB Enzymes / BASF / dsm-firmenich

Germany/NL

H&B enzymes

—

Enzyme competition

Competitor Detail

MetricIFF (FY2025, reported)

Revenue

US$10.89bn

Organic / comparable growth (%)

2

Adjusted EBITDA margin (%)

19.2 (continuing H1 2026: 21.8)

R&D intensity (% of sales)

6.4

Company Snapshot

$10,890M

Revenue

21,500

Employees

$19,800M

Market Cap

1889

Founded

SWOT Analysis

Strengths

  • High-margin biosciences franchise: H&B adj. EBITDA margin 26.0% FY2025; 25.0% Q2 2026
  • Improving continuing-ops margin profile: Continuing H1 2026 adj. EBITDA margin 21.8% vs. 19.2% total company FY2025
  • Demonstrated productivity delivery: FY2025 comparable currency-neutral EBITDA +7% on +2% sales
  • Deleveraging track record: Net debt/credit-adj. EBITDA 3.8x (end-2024) → 2.6x (end-2025) → 2.5x (Q2 2026); S&P upgrade to BBB
  • Volume momentum: Q2 2026 comparable currency-neutral sales +6%, all three segments growing
  • Experienced, refreshed leadership: CEO with DuPont N&B, Syngenta and Nalco background; nine of ten directors independent; separate Chair

Weaknesses

  • Weak GAAP profitability: FY2025 net loss US$(374)m; Q2 2026 continuing EPS US$0.13
  • Heavy intangibles: Goodwill & intangibles US$14.3bn = 56% of FY2025 total assets
  • Thin free cash flow in 2025: FCF US$256m (2.4% of sales)
  • Scent margin erosion: Scent adj. EBITDA margin 22.3% → 20.8% (FY2024→FY2025)
  • Recurring non-operating costs: FY2025: divestiture costs US$125m, regulatory costs US$106m, restructuring US$70m
  • Inventory intensity: DIO ~118 days FY2025 vs. ~106 FY2024 (analyst calculation)

Opportunities

  • Re-rating as a focused F&F/biosciences pure play: FI sold at ~10x EBITDA; continuing business margin ~22%
  • Capital return: US$2.5bn buyback (~12–13% of market cap at ~US$19.8bn) by end-2027
  • Further deleveraging: >US$1bn debt reduction from CVC proceeds; target 2.0–2.5x
  • Biosciences growth vectors: Grain Processing, Food Biosciences, Animal Nutrition leading growth; Omni-Bos™ PHY
  • Fine-fragrance innovation: Double-digit FY2025 growth; AQUASCENT™
  • AI-enabled productivity: GBS expansion; 2026 AI Policy

Threats

  • Antitrust fines and civil damages: EC/CMA/COMCO/Mexico ongoing; India second probe (Jul 2026); Q2 2026 regulatory costs US$71m incl. provisions
  • Input-cost inflation with pricing lag: Management: pricing a modest benefit at best in H2 2026; recovery in 2027
  • Geopolitical demand shocks: Middle East conflict slowed Fine Fragrance in Q2 2026; Russia sanctions hit FI
  • Deal-completion risk: CVC close requires regulatory approvals; expected end-Q2 2027
  • Stranded costs: ~US$100m to remediate post-close
  • Consumer-volume risk: GLP-1 drug adoption and trade-down cited as changing food habits (Reuters, May 2026)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 May 2025Pharma Solutions sale to Roquette closes~US$2.7bn net proceeds received in H1 2025
1 May 2025AGM: O'Byrne elected Chair; 10 directors elected; PwC ratifiedGovernance refresh
5 May 2025S&P revises outlook to positive (BBB-) on bond tender using Pharma proceedsCredit improvement
9 May 2025Nitrocellulose divestedPharma segment exit complete
Q2 2025Tender offers completed; US$488m gain on extinguishmentLower interest burden (FY2025 interest −25%)
Q2 2025US$1,153m goodwill impairment, Food Ingredients reporting unitSignals FI value below book
Jun–Sep 2025Drosos (Jun), Fribourg and Mantas (Jul) join boardBoard refresh
1 Sep 2025Flavors & Essences UK divestedPruning
Sep 2025Agreement to sell Thomson, Illinois site to JungbunzlauerAsset optimisation
20 Oct 2025Brett Icahn and Richard Mulligan join boardIcahn agreement
Nov 2025Q3 2025 results beat consensus; guidance maintainedExecution credibility
1 Dec 2025René Laurent (France) divestedPruning
Q4 2025Food Ingredients sale process launched; US$500m buyback authorisedStrategic pivot
5 Feb 2026US DOJ closes fragrance antitrust investigationRemoves US criminal risk (civil and non-US matters continue)
11 Feb 2026FY2025 results: sales US$10.89bn; adj. EBITDA US$2.086bn; GAAP EPS US$(1.46); 2026 guidance US$10.5–10.8bn salesMet 2025 commitments
27 Feb 2026FY2025 Form 10-K filedAnnual disclosure
2 Mar 2026SCL business sale to Bunge closesPartial FI exit
Mar 2026AI Policy and AI Governance Framework introducedGovernance
18 Mar 20262026 Proxy filed; CEO FY2025 pay US$15.0mGovernance
29 Apr 2026AGM: 10 directors elected; say-on-pay approvedGovernance
5 May 2026Q1 2026 results: adj. EBITDA US$568m; net leverage 2.5x; guidance reaffirmedSteady execution
Late May 2026Media report IFF close to selling Food Ingredients to CVC for >US$4bnPre-announcement leak
29 May 2026Definitive agreement: Food Ingredients to CVC (EV ~US$4.3bn)Transformational
2026 (date not confirmed)S&P upgrades IFF to BBB (from BBB-), short-term A-2, outlook stableCredit upgrade
2026LMR Naturals showcases at SIMPPAR (Paris)Naturals positioning
2026AQUASCENT™ launchedScent innovation
2026Omni-Bos™ PHY launchedH&B innovation
2026Brazil enzyme centre and application lab openedLatAm footprint
2026New investigations in Singapore and India into fragrance-industry employment practicesRegulatory overhang widens
20 Jul 2026Agreement to sell botanicals/vitamins/colours portfolio to SuanNutraFurther pruning
22 Jul 2026Competition Commission of India opens second case (alleged price cartelisation since 2024) per ReutersNew antitrust exposure
28 Jul 2026Q3 2026 dividend US$0.40 declared (payable 9 Oct 2026)Dividend maintained
4 Aug 2026Q2 2026 results; Food Ingredients reclassified to discontinued ops; continuing-ops guidance; US$2.5bn buyback incl. US$500m ASRCapital return pivot
5 Aug 2026Q2 call flags H2 input-cost inflation (energy, logistics), pricing lag to 2027, ~US$100m WC headwindNear-term caution
Aug 2026Q2 adjusted EPS US$0.82 vs. a Zacks consensus of US$1.14 (consensus basis likely pre-recast; comparability questionable)Sentiment drag
25 Aug 2026Reuters reports second CCI probe into Givaudan, Firmenich and IFFRegulatory

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Net sales fell from USD 11,656 Mn in FY2021 to USD 10,890 Mn in FY2025.
International Flavors & Fragrances Inc. (IFF) — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Net sales11,65612,44011,47911,48410,890
Cost of sales———7,3606,952
Gross profit———4,1243,938

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. IFF Q2 2026 results release (4 Aug 2026), Business Wire (businesswire.com)
  2. IFF Q2 2026 8-K exhibit (SEC) (sec.gov)
  3. IFF Q2 2026 10-Q (SEC) (sec.gov)
  4. IFF Q4/FY2025 results release (11 Feb 2026), Business Wire (businesswire.com)
  5. IFF Q1 2026 results release (5 May 2026) (businesswire.com)
  6. IFF 2026 Proxy Statement (DEF 14A, 18 Mar 2026) (sec.gov)
  7. IFF 2025 Proxy Statement (DEF 14A) (sec.gov)
  8. IFF FY2025 Annual Report (ARS) (sec.gov)
  9. 8-K, CVC Transaction Agreement (1 Jun 2026) (sec.gov)
  10. IFF press release, sale of Food Ingredients to CVC (29 May 2026) (sec.gov)
  11. 8-K, 2026 AGM results (ir.iff.com)
  12. Bloomberg Law, IFF to sell Food Ingredients to CVC (news.bloomberglaw.com)
  13. CTV News / Reuters, IFF food-ingredients sale (ctvnews.ca)
  14. The Deal, SuanNutra acquisition (thedeal.com)
  15. ChemXplore, SuanNutra deal details (chemxplore.com)
  16. BeautyMatter, IFF company scale (beautymatter.com)
  17. IFF executive leadership announcement (20 Feb 2025) (businesswire.com)
  18. IFF CFO appointment (Dec 2024) (streetinsider.com)
  19. TipRanks, 2025 board changes (tipranks.com)
  20. Khaleej Times / Reuters, India CCI second probe (25 Aug 2026) (khaleejtimes.com)
  21. PYMNTS, India antitrust and US$26m settlement (pymnts.com)
  22. Cosmetics Business, 2023 fragrance antitrust raids (cosmeticsbusiness.com)
  23. S&P outlook revision (May 2025) (alacrastore.com)
  24. Parqet, S&P upgrade to BBB and analyst distribution (app.parqet.com)
  25. StockAnalysis, price and analyst targets (stockanalysis.com)
  26. IFF Q3 2026 dividend (barchart.com)
  27. GuruFocus, Q2 2026 earnings call summary (gurufocus.com)
  28. StatementDog, Q4 2025 call transcript (statementdog.com)
  29. CNHI News / Zacks, Q2 2026 analysis (cnhinews.com)
  30. Walnut Invest, IFF capital-return summary (walnutinvest.com)
  31. Boardroom Alpha, AGM 8-K and TSR data (boardroomalpha.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.